Clinical Trials Logo

Dermatologic Disease clinical trials

View clinical trials related to Dermatologic Disease.

Filter by:

NCT ID: NCT03578718 Not yet recruiting - Pediatric ALL Clinical Trials

Evaluation of the Interest of a Specialist in Dermatology for Dermatopediatric Consultations

HLSkinPed
Start date: June 25, 2018
Phase:
Study type: Observational

Dermatologic diseases, of very different etiology and variable severity, represent a major motivation for consultation (in private consultations and in emergency departments), thus leading pediatricians to frequently turn to dermatologic advice. The principal aim is to estimate the degree of concordance of the main diagnosis between a pediatrician and a pediatric dermatologist. The secondary aims is to estimate the degree of concordance of the treatment, advices and follow-up.

NCT ID: NCT03471819 Not yet recruiting - Clinical trials for Dermatologic Disease

Serotonin Levels in Atopic Dermatitis Patients

Start date: April 1, 2018
Phase:
Study type: Observational

Atopic dermatitis (AD) is a chronic pruritic inflammatory skin disease of unknown aetiology. Global prevalence rates range from 1%-20%.AD is often worsened by stress and anxiety.Plasma levels of 5-HT were found to be positively correlated with the disease severity.

NCT ID: NCT03047733 Completed - Vitiligo Clinical Trials

Comparison of Cyclic On-off and Continuous Excimer Laser Treatment for Vitiligo

Start date: July 21, 2015
Phase: N/A
Study type: Interventional

OBJECTIVE: To investigate the efficacy of the cyclic on-off treatment compared to the conventional continuous excimer laser treatment. DESIGN: A randomized, controlled, split-body, non-inferiority study. SETTING: The trial was performed in two tertiary health care centers in Korea. PARTICIPANT: Twelve patients (16 pairs of lesions) with stable symmetric vitiligo less than 5 years' disease duration were enrolled. INTERVENSION: The paired symmetric vitiliginous lesions were randomized to either the continuous or the cyclic on-off treatment. All lesions were treated twice weekly for 9-month: continuously, or cyclically with 2-month treatment and 1-month intermission (total 3 cycles). Topical tacrolimus was applied throughout the trial. OUTCOME MEASURES: The repigmentation was assessed using an image analysis program with clinical photographs. The primary outcome was mean difference of repigmentation rates and the non-inferiority margin was set at 10%. During intermission period, the clinical changes such as loss of repigmentation or worsening of the vitiligo lesions were assessed.